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Objectives. This study was designed to verify initial observa-
tions of the clinical and prognostic features of hypertrophic
cardiomyopathy caused by cardiac troponin T gene mutations.
Background. The most common cause of sudden cardiac death
in the young is hypertrophic cardiomyopathy, which is usually
familial. Mutations causing familial hypertrophic cardiomyopa-
thy have been identified in a number of contractile protein genes,
raising the possibility of genetic screening for subjects at risk. A
previous report suggested that mutations in the cardiac troponin
T gene were notable because they were associated with a particu-
larly poor prognosis but only mild hypertrophy. Given the vari-
ability of some genotype:phenotype correlations, further analysis
of cardiac troponin T mutations has been a priority.
Methods. Deoxyribonucleic acid from subjects with hypertro-
phic cardiomyopathy was screened for cardiac troponin T muta-
tions using a ribonuclease protection assay. Polymerase chain
reaction-based detection of a novel mutation was used to genotype
members of two affected pedigrees. Gene carriers were examined
by echocardiography and electrocardiology, and a family history
was obtained.
Results. A novel cardiac troponin T gene mutation, arginine 92
tryptophan, was identified in 19 of 48 members of two affected
pedigrees. The clinical phenotype was characterized by minimal
hypertrophy (mean [6SD] maximal ventricular wall thickness
11.3 6 5.4 mm) and low disease penetrance by clinical criteria
(40% by echocardiography) but a high incidence of sudden cardiac
death (mean age 17 6 9 years).
Conclusions. These data support the observation that appar-
ently diverse cardiac troponin T gene mutations produce a
consistent disease phenotype. Because this is one of poor progno-
sis, despite deceptively mild or undetectable hypertrophy, geno-
typing at this locus may be particularly informative in patient
management and counseling.
(J Am Coll Cardiol 1997;29:549–55)
q1997 by the American College of Cardiology
The annual incidence of sudden death is reported to be
between 19 and 159/100,000 male subjects, representing up to
50% of all deaths in industrialized countries (1); it is believed
that sudden cardiac death comprises a major component of
this figure. This form of death brings particular sorrow, espe-
cially when it occurs unexpectedly in healthy young subjects.
One of the commonest causes of sudden cardiac death in the
adolescent to 35-year old age group is hypertrophic cardiomy-
opathy (2,3). The majority of hypertrophic cardiomyopathy is
familial, in which case relatives of the deceased are also at risk
of sudden cardiac death (4). Frequently, the questions asked
are whether the death was avoidable and whether it is possible
to identify other high risk family members. The clinical heter-
ogeneity and incomplete penetrance that are hallmarks of
familial hypertrophic cardiomyopathy have confounded an-
swers to these queries (5). There is no consistent correlation of
reported risk indicators, such as substantial left ventricular
hypertrophy, recurrent syncope or nonsustained ventricular
tachycardia on Holter monitoring, and the occurrence of
sudden cardiac death (6–8).
The identification of familial hypertrophic cardiomyopathy-
causing mutations in the genes encoding sarcomeric contractile
proteins, namely the beta-myosin heavy chain (9), cardiac
troponin T (10), alpha-tropomyosin (10) and cardiac myosin-
binding protein C (11,12), offers another approach to defining
risk prognosticators. Several genotype:phenotype evaluations
of specific beta-myosin heavy chain gene mutations and the
associated spectrum of clinical features, including the risk of
sudden cardiac death, have been reported in familial hypertro-
phic cardiomyopathy (13,14). The presence of symptomatic
gene carriers (incomplete penetrance), which may exceed 25%
in some families, has been a noticeable feature of the studies
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(13). As a result of these assessments, mutations have been
categorized as malignant or benign (14). However, the corre-
lations have not proved invariable; reports of discrepancies in
beta-myosin heavy chain gene-caused familial hypertrophic
cardiomyopathy genotype:phenotype correlations exist (13,15).
In addition, the value of genetic screening may also be limited
in beta-myosin heavy chain gene-caused familial hypertrophic
cardiomyopathy because cardiac hypertrophy is generally clin-
ically apparent in subjects with malignant mutations and
because the large size of the gene hampers mutation detections
(14).
Recent findings (10) have focused attention on the role of
cardiac troponin T gene mutations, which may account for at
least 15% of cases of familial hypertrophic cardiomyopathy.
The eight different cardiac troponin T gene mutations de-
scribed fall into three classes, namely, missense, in-frame
deletion and splice donor site mutations. The only reported
study of genotype:phenotype correlations to date (10) showed
that the clinical features associated with all these cardiac
troponin T gene mutations were remarkably similar despite the
distinct types of gene defects that would be expected to
produce different classes of dysfunctional product. The average
maximal ventricular wall thickness associated with cardiac
troponin T gene mutations was considerably less than that
recorded in beta-myosin heavy chain gene-caused familial
hypertrophic cardiomyopathy, with an associated reduction of
disease penetrance. However, the number of disease-related
and sudden cardiac deaths attributable to cardiac troponin T
gene mutations was high, similar to that seen with the most
malignant beta-myosin heavy chain gene mutations.
If frequent sudden cardiac death, in the setting of mild to
undetectable hypertrophy and the presence of asymptomatic
gene carriers, is characteristic of cardiac troponin T gene-
caused familial hypertrophic cardiomyopathy, then mutation
detection in this gene may be of particular clinical relevance.
Therefore, further genotype:phenotype studies in large fami-
lies in different geographical areas are needed to evaluate the
role of other cardiac troponin T gene mutations in the
development of familial hypertrophic cardiomyopathy and to
assess their prognostic implications.
In the present study, we describe genotype:phenotype cor-
relations of familial hypertrophic cardiomyopathy resulting
from a novel cardiac troponin T gene, arginine 92 tryptophan
mutation, in two South African families of mixed racial de-
scent, revealing the insidious nature of defects in this gene.
Methods
Patient study group and clinical evaluation. The study was
performed according to institutional ethics committee ap-
proval. Informed consent was obtained from subjects or from
parents of minors participating in the study. Pedigree 0,
reported in a previous study as pedigree 100 (16), and pedigree
9, described in the present study, both of mixed racial descent,
were established from familial hypertrophic cardiomyopathy-
affected probands in whom no beta-myosin heavy chain gene
mutations had been detected. Members of the two pedigrees
were identified by the prefix 0 or 9, followed by generation and
individual numbers. Family members were traced, and the
history of disease-related and sudden cardiac deaths was
established. All available members of pedigree 0 had been
examined clinically during the earlier study. Among newly
traced members of pedigree 0 and pedigree 9, only those
genotypically positive for the arginine codon 92 tryptophan
mutation were examined clinically.
Clinical examination was performed as previously described
(13). Briefly, echocardiographic diagnosis of familial hypertro-
phic cardiomyopathy was made in the presence of a maximal
ventricular wall thickness $13 mm. In children, diagnosis was
made with reference to age-adjusted tables. Electrocardio-
graphic diagnosis of familial hypertrophic cardiomyopathy was
based on the presence of left ventricular hypertrophy or
abnormal Q waves. Other echocardiographic and electrocar-
diographic (ECG) changes previously described in familial
hypertrophic cardiomyopathy were noted for each patient.
Source of DNA and DNA extraction. After informed con-
sent was obtained, peripheral blood for genotypic analysis was
collected from all probands and family members entered into
the study, and DNA was extracted as previously described (17).
Mutation detection. Linkage analysis excluded a beta-
myosin heavy chain gene mutation as the cause of familial
hypertrophic cardiomyopathy in pedigree 0 (16); support for
linkage was obtained with markers linked to the cardiac
troponin T gene locus (data not shown). Consequently, cardiac
troponin T messenger RNAs derived from two affected mem-
bers of pedigree 0 were screened by ribonuclease protection
assays, as previously described (10). Abnormal cleavage prod-
ucts (indicative of sequence differences) were sequenced ac-
cording to standard protocols.
Polymerase chain reaction-based detection of the arginine
92 tryptophan mutation, which resulted in the loss of an MspI
restriction enzyme site in exon 9 of the cardiac troponin T
gene, was used to identify genotypically positive relatives in
pedigrees 0 and 9. Exons 8 and 9, with the intervening intron,
were polymerase chain reaction amplified using primers 214F
and 393R (using the numbering system of Mesnard et al. [18])
to generate a 498 base pair product for digestion with MspI
(19), according to previously described methods (13).
Results
Mutation screening and detection. Linkage analysis in
pedigree 0 indicated that familial hypertrophic cardiomyopa-
thy in this family was linked to the region of the cardiac
troponin T gene. Ribonuclease protection assays of cardiac
troponin T complementary DNA acid identified a sequence
variant in exon 9 of two affected subjects from pedigree 0.
Nucleotide sequencing revealed a previously undescribed cy-
tosine to thymine transition at nucleotide 286, the first base of
codon 92. This modification results in the substitution of
arginine by tryptophan at this position in the protein, fortu-
itously resulting in the loss of an MspI site and thus allowing
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polymerase chain reaction-based restriction enzyme mutation
detection. The presence of three bands in the digested product
of polymerase chain reaction-amplified exon 9 of an affected
subject would indicate the presence of both the normal and
mutated allele.
Subsequently, the MspI-based detection assay also identi-
fied heterozygous loss of the restriction enzyme recognition
sequence in exon 9 of the proband of pedigree 9. Nucleotide
sequencing revealed the same cytosine to thymine transition in
the first base of codon 92 that had been detected in the
proband of pedigree 0. This mutation was not detected in 100
unrelated, unaffected control subjects.
Disease penetrance and clinical features of the arginine 92
tryptophan mutation. Nineteen of the 48 genotyped members
of the two pedigrees carried the arginine 92 tryptophan
mutation (Fig. 1), and 18 of these were examined clinically. In
addition, subjects 0.II.7 and 0.II.14 were obligate gene carriers
by virtue of having transmitted the mutation to some of their
children; individual 0.IV.2 was genotypically positive, but had
not been examined clinically. The standard echocardiographic
diagnostic criterion of a ventricular wall thickness$13 mm was
met in only six subjects, shown in bold in Table 1. The average
maximal wall thickness, calculated for subjects $16 years in
both pedigrees, was 11.3 6 5.4 mm (mean 6 SD, n 5 14),
within the normal range. Electrocardiographic abnormalities
characteristic of familial hypertrophic cardiomyopathy were
also seen in four of the six persons with overt hypertrophy. In
the remaining two, subject 0.III.15 exhibited normal ECG
results, whereas the abnormalities present in subject 9.III.1
were not specific for hypertrophy. An additional six family
members who displayed no echocardiographic evidence of
familial hypertrophic cardiomyopathy possessed characteristic
ECG abnormalities (Table 1). Another six subjects were
genotypically positive but showed no evidence of hypertrophy
and had either normal ECG patterns or nonspecific abnormal-
ities (Table 1). Three of the gene carriers with normal clinical
studies were .16 years old, namely subjects 0.II.18, 0.III.20
and 9.III.5, who were 47, 27 and 28 years old, respectively.
The disease penetrance in subjects.16 years old calculated
for the combined pedigrees was 40% by echocardiography
when the standard diagnostic criterion of ventricular wall
thickness was applied and 66% when characteristic ECG
features were applied. The penetrance was 80% on the basis of
both echocardiographic and ECG abnormalities characteristic
of the disease.
The range of symptoms varied, with presyncope or syncope
expressed in three subjects, dyspnea in seven, angina in three
and palpitations in three (data not shown). Sudden cardiac
death at a young age was frequent in pedigree 0, occurring in
six subjects (Fig. 1) and possibly two other young subjects
whose deaths cannot be directly attributable to the disease. In
subjects 0.II.5 and 9.III.7, the cause of death was a tumor and
a motor vehicle accident, respectively. Three subjects died of a
cerebral vascular accident, at ages ranging from 38 to 62 years.
Of these, 0.II.7 was an obligate heterozygote, 0.II.20 was
unlikely to be a gene carrier because he had a number of
unaffected children, and 0.II.2, who had marked concentric
hypertrophy and long-standing hypertension, was genotyped
after death and did not carry the mutation. In pedigree 9, one
sudden cardiac death at age 28 years, with characteristic
pathology of familial hypertrophic cardiomyopathy found on
post mortem, was reported. The mean age of sudden cardiac
death in the two families studied was 17 6 9 years.
Survival analysis in the two families highlighted the strik-
ingly high incidence of sudden cardiac death in adolescents and
young adults (Fig. 2). However, the cumulative mortality rate
did not reach 50% in these kindreds (see Discussion). The
prognosis for the arginine 92 tryptophan mutation appeared
particularly poor for male subjects. Although 14 of the 18
genotypically positive family members were female, all of the
sudden cardiac deaths occurred in young male subjects. The
cumulative mortality rate for male subjects only was 64% by 28
years.
The clinical features associated with familial hypertro-
phic cardiomyopathy in the two pedigrees are summarized
in Table 2.
Discussion
Identification of novel cardiac troponin T gene mutation.
A novel cardiac troponin T gene, arginine 92 tryptophan
mutation, was identified and shown to cause familial hypertro-
phic cardiomyopathy in two pedigrees. The mutation was
present in all clinically affected relatives. In addition, a number
of clinically unaffected relatives with the mutation were iden-
tified, confirming that incomplete penetrance is a feature of
familial hypertrophic cardiomyopathy caused by cardiac tropo-
nin T gene mutations. The arginine 92 tryptophan mutation
was not present in 100 unaffected unrelated subjects of mixed
racial ancestry. Previous reports (19) have described an argi-
nine 92 glutamine mutation in the same cardiac troponin T
codon, which invariably codes for a basic residue in vertebrate
species. Evidence that the arginine 92 glutamine mutation
must have arisen on at least three independent occasions (10)
and the fact that the two mutations occur at a mutationally
fragile cytosine:guanine doublet within codon 92, suggest that
this is a mutation hotspot (20). Identification of regions of the
cardiac troponin T gene sequence prone to disease-causing
mutation may simplify mutation screening in unrelated fami-
lies.
Clinical and prognostic features of cardiac troponin T gene
mutations. Clinical and prognostic evaluations were based on
combined data for the two pedigrees because they share the
same arginine 92 tryptophan mutation. The latter was charac-
terized by mild, often undetectable, hypertrophy; the mean
maximal wall thickness of affected adults was in the normal
range (11.3 6 5.4 mm). This was reflected in the low pen-
etrance of only 40% when based on standard echocardio-
graphic definition and 66% by electrocardiography. However,
despite the apparent mildness of symptoms and hypertrophy,
the prognosis associated with this mutation was extremely
poor, particularly for adolescent and young adult male sub-
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jects. The cumulative mortality rate was 34% among both
genders, but 64% for male subjects, at the age of 28 years. The
combined cumulative mortality rate did not reach 50% in these
families. Two explanations may be proposed: 1) The family
members studied were of relatively young age, providing little
data regarding later life; 2) there were no late deaths due to
Figure 1. Diagrams of pedigrees of two families carrying the familial hypertrophic
cardiomyopathy-causing cardiac troponin T gene arginine 92 tryptophan mutation. The
genotypic and phenotypic status of subjects is indicated in the key. Subjects 0.II.7 and 0.II.14
were obligate heterozygotes, and 9.III.3 had characteristic features of familial hypertrophic
cardiomyopathy on postmortem examination; however, no postmortem tissue was available
for genotyping.
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progressive heart failure in this group. This observation is
consistent with data from other cardiac troponin T gene
mutations studied, where the survival curves also suggested a
plateau after the third decade, and where later deaths from
heart failure were rare (10). These data confirm earlier obser-
vations (10) that the clinical features of cardiac troponin T
gene mutations may be distinguished from those associated
with beta-myosin heavy chain gene defects, where malignant
mutations are generally associated with clinically obvious
disease. In addition, data from this study highlight the possi-
bility that cardiac troponin T gene mutations are less prone to
lead to congestive heart failure than are mutations in the
beta-myosin heavy chain gene. It is tempting to speculate about
the relation between this observation and the noted differences
in the severity of hypertrophy.
Genotype:phenotype correlations in hypertrophic cardio-
myopathy. Initial genotype:phenotype correlations of beta-
myosin heavy chain gene-caused familial hypertrophic cardio-
myopathy suggested that variations resulting in a change in
charge of the substituted amino acid were associated with a
poor survival index (14,21). However, the effects of various
mutations on prognosis are probably more complex (22,23). In
particular, it has not proved possible to predict the effect of a
mutation by extrapolation from phenotypes of apparently
similar mutations. For example, a cytosine:guanine mutation
hotspot responsible for familial hypertrophic cardiomyopathy
has also been described (24) in the beta-myosin heavy chain
Figure 2. Kaplan-Meier product-limit curves for survival in subjects in
familial hypertrophic cardiomyopathy families carrying the arginine 92
tryptophan mutation.







ECG and Echocardiographic Abnormalities
0.II.10 F/56 LVH, LAH S 5 14, P 5 12, mild TI, fibrosis of MV
0.II.12 F/57 LVH, RAH S 5 13, P 5 12
0.II.23 F/41 LVH, LAH, RAH S 5 12, P 5 13, SAM, mild TI
0.III.9 F/28 LVH, LAH S 5 24, P 5 11, mild TI
9.III.1 F/34 Increased voltages, predominant R wave* in lead V1 S 5 18–20, P 5 11, SAM, ASH
Echocardiographic Abnormalities Only
0.III.15 F/35 — S 5 13.8, P 5 7.5, SAM, ASH
ECG Abnormalities Only
0.III.5 F/23 Increased voltages; inferior and lateral Q waves S5 6, P 5 6
0.III.7 M/21 Inferior and lateral Q waves
0.III.8 M/38 Lateral Q waves S 5 9, P 5 9
0.III.12 F/35 Inferior and lateral Q waves S5 8, P 5 8
0.III.17 M/28 Increased voltages, inferior and lateral Q waves,
predominant R wave in lead V1
S 5 7, P 5 8
9.II.1 F/56 LVH, LAH S 5 8, P 5 7
None/Nonspecific Abnormalities
0.II.18 F/47 Nonspecific T wave changes S5 7, P 5 7
0.III.20 F/27 Short PR interval S 5 6, P 5 6
0.III.22 F/9 Normal S 5 4, P 5 4
9.III.5 M/28 QRS axis (2408 NW) S 5 8.5, P 5 8.5
9.IV.1 F/15 Normal S 5 5, P 5 5
9.IV.2 F/11 Increased voltages, predominant R wave in lead V1 S 5 7, P 5 7
*Nonspecific electrocardiographic (ECG) changes. Boldface indicates subjects with echocardiographic familial hypertensive cardiomyopathy diagnostic criterion of
left ventricular hypertrophy (LVH) $13 mm. ASH 5 asymmetric septal hypertrophy; F 5 female; M 5 male; LAH 5 left atrial hypertrophy; MV 5 mitral valve; P 5
posterior wall thickness (mm); RAH 5 right atrial hypertrophy; S 5 interventricular septal thickness (mm); SAM 5 systolic anterior motion of mitral valve (anterior
leaflet); TI 5 tricuspid valve incompetence.
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gene, where the arginine encoded by codon 403 may be
substituted by either tryptophan or glutamine. In both muta-
tions, a basic residue is replaced by an uncharged one. How-
ever, whereas the beta-myosin heavy chain gene arginine 403
glutamine mutation has a malignant phenotype, the beta-
myosin heavy chain gene arginine 403 tryptophan mutation
was associated with mild hypertrophy and no sudden cardiac
death in two unrelated families (13,25). Therefore, we believe
that independent clinical data, of the type presented here, were
necessary to confirm that there is a characteristic phenotype
among cardiac troponin T gene mutations.
Screening for cardiac troponin T gene mutations. Evi-
dence is accumulating that in familial hypertrophic cardiomy-
opathy, a “monogenic” disorder, the development of the
disease is influenced not only by a major gene and its specific
mutations, but by other contributary factors (13,23,26). How-
ever, in the case of familial hypertrophic cardiomyopathy
caused by cardiac troponin T gene mutations, it appears that
this major gene is strongly predictive of the course of the
disease. The consistent association of a poor prognosis with
deceptively mild clinical features and reduced penetrance
emphasizes the relevance of screening for cardiac troponin T
gene mutations. This process will be facilitated by the relatively
small coding sequence of the cardiac troponin T gene (10) and
the presence of the codon 92 mutation hotspot. We believe
that screening for cardiac troponin T gene mutations will be of
value in families with sudden cardiac death and familial
hypertrophic cardiomyopathy. Moreover, such screening may
be appropriate for first-degree relatives of subjects with sudden
cardiac death where a diagnosis of familial hypertrophic
cardiomyopathy was suspected, for example on histologic
grounds, even in the absence of hypertrophy. Detection of
disease-causing mutations will identify subjects at risk of
sudden cardiac death that will assist in designing and testing
treatment strategies and in patient management and counsel-
ing.
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